The effects of astemizole on histamine-induced weal and flare.
The effect of astemizole on the weal and flare response to intradermal histamine has been studied in normal volunteers after single dosing, and in patients with urticaria and pruritus after chronic dosing with the drug. Single doses of astemizole (40 mg) in normal volunteers significantly reduced histamine weal and flare at 24 and 48 h (p less than 0.001). Before treatment, there was a significantly greater response to intradermal histamine in patients with urticaria than pruritus (p less than 0.05). Chronic dosing with astemizole produced significant reduction in histamine-induced weal and flare in both patient groups which did not show evidence of tachyphalaxis over the period of the study. The effect of astemizole on histamine-induced weal and flare was accompanied by a significant increase in the rate of weal and flare disappearance in both patients (weal p less than 0.002, flare p less than 0.05) and volunteers (weal p less than 0.02, flare p less than 0.005); but there was no change in the rate of weal formation. The effects of astemizole on weal and flare kinetics may be a function of its high level of H1 antagonist activity.
D000328:Adult; D000368:Aged; D016589:Astemizole; D001562:Benzimidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D004342:Drug Hypersensitivity / Q000188:drug therapy*; D004347:Drug Interactions; D005260:Female; D006632:Histamine / Q000009:adverse effects*; D006635:Histamine H2 Antagonists; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000139:chemically induced / Q000188:drug therapy*; D007271:Injections, Intradermal; D008297:Male; D008875:Middle Aged; D011537:Pruritus / Q000188:drug therapy; D014581:Urticaria / Q000188:drug therapy
D001562:Benzimidazoles; D006635:Histamine H2 Antagonists; D016589:Astemizole; D006632:Histamine